Discovery methods of coagulation-inhibiting drugs
A Gomez-Outes, M Garcia-Fuentes… - Expert Opinion on …, 2017 - Taylor & Francis
Introduction: In the last decade, several direct oral anticoagulants (DOAC) targeting thrombin
(dabigatran) or activated factor X (FXa)(rivaroxaban, apixaban and edoxaban) have been …
(dabigatran) or activated factor X (FXa)(rivaroxaban, apixaban and edoxaban) have been …
Discovery methods of coagulation-inhibiting drugs.
A Gómez-Outes, M García-Fuentes… - Expert Opinion on …, 2017 - europepmc.org
In the last decade, several direct oral anticoagulants (DOAC) targeting thrombin (dabigatran)
or activated factor X (FXa)(rivaroxaban, apixaban and edoxaban) have been marketed for a …
or activated factor X (FXa)(rivaroxaban, apixaban and edoxaban) have been marketed for a …
Discovery methods of coagulation-inhibiting drugs
A Gómez-Outes, M García-Fuentes… - Expert opinion on …, 2017 - pubmed.ncbi.nlm.nih.gov
In the last decade, several direct oral anticoagulants (DOAC) targeting thrombin (dabigatran)
or activated factor X (FXa)(rivaroxaban, apixaban and edoxaban) have been marketed for a …
or activated factor X (FXa)(rivaroxaban, apixaban and edoxaban) have been marketed for a …
[引用][C] Discovery methods of coagulation-inhibiting drugs
A Gómez-Outes, M García-Fuentes… - Expert Opinion on Drug …, 2017 - cir.nii.ac.jp
Discovery methods of coagulation-inhibiting drugs | CiNii Research CiNii 国立情報学研究所
学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学 …
学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学 …